Medicamen Biotech Limited has informed the Exchange that Record date for the purpose of Dividend is 19-Sep-2025.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech's board approved unaudited standalone and consolidated results for Q1 FY26 (quarter ended June 30, 2025), with the auditor issuing an unmodified (clean) limited review opinion. On a standalone basis, total revenue fell to about Rs. 38.9 crore from Rs. 42.1 crore a year ago, and net profit dropped to about Rs. 1.64 crore from Rs. 2.26 crore — a roughly 27% year-on-year decline in profit. Consolidated performance was steadier, with revenue nearly flat at Rs. 43.5 crore and net profit at Rs. 1.60 crore versus Rs. 1.35 crore last year. The board also recommended a final dividend of Re. 1 per share (10%) for FY25, subject to shareholder approval, set the record date as September 19, 2025, and scheduled the 32nd AGM for September 26, 2025. Additionally, two new Independent Directors (Sham Goel and Shaival Saurabh) were appointed, and Ashwani Kumar Sharma was redesignated as Whole-time (Executive) Director for five years.
The weaker standalone Q1 numbers — revenue down and profit falling over a quarter — may weigh on short-term sentiment, though the clean audit opinion and proposed dividend provide some support. Investors should watch for the AGM outcome and the full-year performance, as the appointments also signal board renewal ahead of the upcoming independent director term expirations.